{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:40Z","timestamp":1790688580987,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0501000"],"award-info":[{"award-number":["2023ZD0501000"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024B1515120038"],"award-info":[{"award-number":["2024B1515120038"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-0017"],"award-info":[{"award-number":["CIRP-SYSUCC-0017"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403689"],"award-info":[{"award-number":["82403689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nasopharyngeal carcinoma (NPC) continues to represent a significant therapeutic challenge. Despite the substantial success of radiotherapy, chemotherapy, and immunotherapy, their effectiveness remains limited in recurrent or advanced NPC. Hence, the urgent identification of new molecular targets and effective therapeutic agents is critically required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bulk and single-cell transcriptomic data were analyzed using bioinformatics approaches, and machine learning algorithms were employed to screen for hub genes in NPC. Functional validation of hub genes was performed through loss-of-function assays. Potential therapeutic agents were identified through molecular docking and subsequently evaluated for anti-NPC efficacy using both in vitro NPC cell line models and in vivo patient-derived xenograft (PDX) models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bioinformatics analyses revealed\n                      <jats:italic>DTL<\/jats:italic>\n                      as a central gene with critical diagnostic and prognostic significance. Knockdown of\n                      <jats:italic>DTL<\/jats:italic>\n                      led to cell cycle arrest and apoptosis through stabilization of p21 and p53. Pevonedistat markedly inhibited DTL activity, recapitulating the effects of\n                      <jats:italic>DTL<\/jats:italic>\n                      knockdown. In vitro studies showed that Pevonedistat suppressed NPC cell proliferation, while in PDX models it significantly reduced tumor burden. Collectively, the data establish\n                      <jats:italic>DTL<\/jats:italic>\n                      as a key oncogenic driver in NPC and highlight Pevonedistat as a promising therapeutic candidate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our work presents an integrated framework for target identification and therapeutic development in NPC. These findings deepen our understanding of NPC biology and highlight that Pevonedistat suppresses cell proliferation and tumor growth of NPC via the CRL4-DTL-p21\/p53 axis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00661-2","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:02:37Z","timestamp":1772863357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated bioinformatics analysis and experimental validation reveal Pevonedistat as a promising therapeutic agent modulating the CRL4\u2013DTL\u2013p21\/p53 axis in nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"163","author":[{"given":"Cong-Chao","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"10192","key":"661_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London England). 2019;394(10192):64\u201380.","journal-title":"Lancet (London England)"},{"issue":"1","key":"661_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12967-023-04673-8","volume":"21","author":"PY Siak","year":"2023","unstructured":"Siak PY, Heng WS, Teoh SSH, Lwin YY, Cheah SC. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect. J translational Med. 2023;21(1):786.","journal-title":"J translational Med"},{"issue":"1","key":"661_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01928-2","volume":"23","author":"H Liu","year":"2024","unstructured":"Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H, Xiao T, Yang H, Gu W, Wang H, Chen P. Nasopharyngeal carcinoma: current views on the tumor microenvironment\u2019s impact on drug resistance and clinical outcomes. Mol Cancer. 2024;23(1):20.","journal-title":"Mol Cancer"},{"issue":"6","key":"661_CR4","first-page":"1035","volume":"30","author":"ET Chang","year":"2021","unstructured":"Chang ET, Ye W, Zeng YX, Adami HO. The Evolving Epidemiology of Nasopharyngeal Carcinoma, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. cosponsored Am Soc Prev Oncol. 2021;30(6):1035\u201347.","journal-title":"cosponsored Am Soc Prev Oncol"},{"issue":"1","key":"661_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-021-08311-8","volume":"21","author":"ET Beyene","year":"2021","unstructured":"Beyene ET, Ketema SG, Alebachew AN, Saleh MY, Gebremariam TA. Descriptive epidemiology of nasopharyngeal carcinoma at Tikur Anbessa Hospital, Ethiopia. BMC Cancer. 2021;21(1):540.","journal-title":"BMC Cancer"},{"issue":"1","key":"661_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","volume":"374","author":"LL Tang","year":"2016","unstructured":"Tang LL, Chen WQ, Xue WQ, He YQ, Zheng RS, Zeng YX, Jia WH. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016;374(1):22\u201330.","journal-title":"Cancer Lett"},{"issue":"2","key":"661_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2012.01.009","volume":"22","author":"WH Jia","year":"2012","unstructured":"Jia WH, Qin HD. Non-viral environmental risk factors for nasopharyngeal carcinoma: a systematic review. Sem Cancer Biol. 2012;22(2):117\u201326.","journal-title":"Sem Cancer Biol"},{"issue":"9","key":"661_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cac2.12317","volume":"42","author":"YQ He","year":"2022","unstructured":"He YQ, Xue WQ, Li DH, Wang TM, Mai ZM, Yang DW, Deng CM, Liao Y, Zhang WL, Xiao RW, Luo L, Diao H, Tong X, Wu Y, Zhang JB, Zhou T, Li XZ, Zhang PF, Zheng XH, Zhang SD, Hu YZ, Tang M, Zheng Y, Cai Y, Chang ET, Zhang Z, Huang G, Cao SM, Liu Q, Feng L, Sun Y, Lung ML, Adami HO, Ye W, Lam TH, Jia WH. Transcriptome-wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma. Cancer Commun (London England). 2022;42(9):887\u201391.","journal-title":"Cancer Commun (London England)"},{"key":"661_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1186\/s12885-015-2035-x","volume":"15","author":"YQ He","year":"2015","unstructured":"He YQ, Xue WQ, Shen GP, Tang LL, Zeng YX, Jia WH. Household inhalants exposure and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China. BMC Cancer. 2015;15:1022.","journal-title":"BMC Cancer"},{"key":"661_CR10","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/CMAR.S341472","volume":"14","author":"R Jiromaru","year":"2022","unstructured":"Jiromaru R, Nakagawa T, Yasumatsu R. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options. Cancer Manage Res. 2022;14:2681\u20139.","journal-title":"Cancer Manage Res"},{"issue":"3","key":"661_CR11","doi-asserted-by":"publisher","first-page":"e251895","DOI":"10.1001\/jamanetworkopen.2025.1895","volume":"8","author":"MB Alsavaf","year":"2025","unstructured":"Alsavaf MB, Marquardt M, Abouammo MD, Xu M, Elguindy A, Grecula J, Baliga S, Konieczkowski D, Gogineni E, Bhateja P, Rocco JW, Old MO, Blakaj DM, Carrau RL, VanKoevering KK, Bonomi M. Patient Characteristics and Treatment Outcomes of Nasopharyngeal Carcinoma in Nonendemic Regions. JAMA Netw open. 2025;8(3):e251895.","journal-title":"JAMA Netw open"},{"issue":"10022","key":"661_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","volume":"387","author":"MLK Chua","year":"2016","unstructured":"Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet (London England). 2016;387(10022):1012\u201324.","journal-title":"Lancet (London England)"},{"key":"661_CR13","doi-asserted-by":"publisher","unstructured":"Huang H, Yao Y, Deng X, et al. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). Int J Oncol. 2023;63(2):97. https:\/\/doi.org\/10.3892\/ijo.2023.5545.","DOI":"10.3892\/ijo.2023.5545"},{"key":"661_CR14","doi-asserted-by":"publisher","first-page":"102840","DOI":"10.1016\/j.ctrv.2024.102840","volume":"131","author":"M Cai","year":"2024","unstructured":"Cai M, Wang Y, Ma H, Yang L, Xu Z. Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma. Cancer Treat Rev. 2024;131:102840.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"661_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11864-023-01101-3","volume":"24","author":"JJ Juarez-Vignon Whaley","year":"2023","unstructured":"Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, Bell D, Villaflor VM. Recurrent\/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading? Curr Treat Options Oncol. 2023;24(9):1138\u201366.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"661_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.7150\/thno.82690","volume":"13","author":"W Luo","year":"2023","unstructured":"Luo W. Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal unity of ecology and evolution pathological ecosystem. Theranostics. 2023;13(5):1607\u201331.","journal-title":"Theranostics"},{"issue":"1","key":"661_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","volume":"5","author":"Y Kang","year":"2020","unstructured":"Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J, Xu H, Jiang X, Wang L. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target therapy. 2020;5(1):245.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"661_CR18","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.bj.2024.100748","volume":"48","author":"CL Hsu","year":"2025","unstructured":"Hsu CL, Chang YS, Li HP. Molecular diagnosis of nasopharyngeal carcinoma: Past and future. Biomedical J. 2025;48(1):100748.","journal-title":"Biomedical J"},{"issue":"8","key":"661_CR19","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1158\/0008-5472.CAN-10-0469","volume":"71","author":"HD Qin","year":"2011","unstructured":"Qin HD, Shugart YY, Bei JX, Pan QH, Chen L, Feng QS, Chen LZ, Huang W, Liu JJ, Jorgensen TJ, Zeng YX, Jia WH. Comprehensive pathway-based association study of DNA repair gene variants and the risk of nasopharyngeal carcinoma. Cancer Res. 2011;71(8):3000\u20138.","journal-title":"Cancer Res"},{"key":"661_CR20","doi-asserted-by":"publisher","unstructured":"Wang B, Gong Q, Chen F. CDC25A inhibition suppresses cell proliferation and induces G1\/S\u2011phase cell cycle arrest in nasopharyngeal carcinoma. Mol Med Rep. 2023;27(5):109. https:\/\/doi.org\/10.3892\/mmr.2023.12996.","DOI":"10.3892\/mmr.2023.12996"},{"issue":"7","key":"661_CR21","doi-asserted-by":"publisher","first-page":"e23055","DOI":"10.1096\/fj.202201628RR","volume":"37","author":"X Li","year":"2023","unstructured":"Li X, Guo Y, Xiao M, Zhang W. The immune escape mechanism of nasopharyngeal carcinoma. FASEB journal: official publication Federation Am Soc Experimental Biology. 2023;37(7):e23055.","journal-title":"FASEB journal: official publication Federation Am Soc Experimental Biology"},{"issue":"1","key":"661_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41392-025-02273-0","volume":"10","author":"GJ Nuovo","year":"2025","unstructured":"Nuovo GJ, Tili E, Croce CM. Nasopharyngeal carcinoma: a model cancer to understand tumor rejection. Signal Transduct Target therapy. 2025;10(1):187.","journal-title":"Signal Transduct Target therapy"},{"issue":"11","key":"661_CR23","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","volume":"30","author":"YP Chen","year":"2020","unstructured":"Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K, Kuang DM, Li GB, Liu N, Ma J. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30(11):1024\u201342.","journal-title":"Cell Res"},{"issue":"1","key":"661_CR24","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ye SY, He S, Chi DM, Wang XZ, Wen YF, Ma D, Nie RC, Xiang P, Zhou Y, Ruan ZH, Peng RJ, Luo CL, Wei PP, Lin GW, Zheng J, Cui Q, Cai MY, Yun JP, Dong J, Mai HQ, Xia X, Bei JX. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat Commun. 2024;15(1):7713.","journal-title":"Nat Commun"},{"issue":"8","key":"661_CR25","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/s41588-025-02253-8","volume":"57","author":"R You","year":"2025","unstructured":"You R, Shen Q, Lin C, Dong K, Liu X, Xu H, Hu W, Xie Y, Xie R, Song X, Huang C, Wu J, Yu T, Li H, Wang Z, Chen K, Zou X, Huang P, Hua Y, Liu Y, Xia T, Zhang S, Chen M. Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma. Nat Genet. 2025;57(8):1950\u201365.","journal-title":"Nat Genet"},{"issue":"1","key":"661_CR26","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s12672-025-02962-w","volume":"16","author":"Z Wei","year":"2025","unstructured":"Wei Z, Wang G, Hu Y, Zhou C, Zhang Y, Shen Y, Wang Y. Machine learning-based identification of exosome-related biomarkers and drugs prediction in nasopharyngeal carcinoma. Discover Oncol. 2025;16(1):1134.","journal-title":"Discover Oncol"},{"issue":"1","key":"661_CR27","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41467-024-46043-y","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang B, Zhao Y, Shao X, Wang M, Ma F, Yang L, Nie M, Jin P, Yao K, Song H, Lou S, Wang H, Yang T, Tian Y, Han P, Hu Z. Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer. Nat Commun. 2024;15(1):1657.","journal-title":"Nat Commun"},{"key":"661_CR28","doi-asserted-by":"publisher","unstructured":"Dancik GM, Vlahopoulos SA. Editorial for the Special Issue: Bioinformatics and Computational Biology for Cancer Prediction and Prognosis. Genes (Basel). 2025;16(2):167. Published 2025 Jan 28. https:\/\/doi.org\/10.3390\/genes16020167.","DOI":"10.3390\/genes16020167"},{"issue":"W1","key":"661_CR29","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022;50(W1):W159\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"661_CR30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s43018-020-00116-1","volume":"1","author":"JF Limzerwala","year":"2020","unstructured":"Limzerwala JF, Jeganathan KB, Kloeber JA, Davies BA, Zhang C, Sturmlechner I, Zhong J, Fierro Velasco R, Fields AP, Yuan Y, Baker DJ, Zhou D, Li H, Katzmann DJ, van Deursen JM. FoxM1 insufficiency hyperactivates Ect2-RhoA-mDia1 signaling to drive cancer. Nat cancer. 2020;1(10):1010\u201324.","journal-title":"Nat cancer"},{"issue":"2","key":"661_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41418-022-01104-x","volume":"30","author":"YF Cao","year":"2023","unstructured":"Cao YF, Xie L, Tong BB, Chu MY, Shi WQ, Li X, He JZ, Wang SH, Wu ZY, Deng DX, Zheng YQ, Li ZM, Xu XE, Liao LD, Cheng YW, Li LY, Xu LY, Li EM. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. Cell Death Differ. 2023;30(2):527\u201343.","journal-title":"Cell Death Differ"},{"issue":"2","key":"661_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jalz.2018.08.013","volume":"15","author":"F Huang","year":"2019","unstructured":"Huang F, Wang M, Liu R, Wang JZ, Schadt E, Haroutunian V, Katsel P, Zhang B, Wang X. CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2019;15(2):217\u201331.","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"5","key":"661_CR33","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s12094-024-03713-z","volume":"27","author":"L Wang","year":"2025","unstructured":"Wang L, Wang M, Wang Z, Wang K, Zhao B, Wang Y, Zheng J, Zhang S. UBE2T is a diagnostic and prognostic biomarker for endometrial cancer. Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2025;27(5):2067\u201383.","journal-title":"Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"key":"661_CR34","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52D1","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin NEL, Strawbridge SA, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R, Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat DY, Jackson H, Harford K, Anjum A, Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQR, Nguyen T, So D, Sharp M, da Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V, Wishart DS. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52D1:D1265\u201375.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"661_CR35","doi-asserted-by":"publisher","first-page":"D1398","DOI":"10.1093\/nar\/gkab953","volume":"50","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y, Chen Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022;50(D1):D1398\u2013407.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"661_CR36","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, F\u00e9lix E, Magari\u00f1os MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Mara\u00f1\u00f3n M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47(D1):D930\u201340.","journal-title":"Nucleic Acids Res"},{"key":"661_CR37","doi-asserted-by":"crossref","unstructured":"Chua MLK, Zhang X, Wong KCW, Gr\u00e9goire M, Spreafico A, Ma B. Updates on Treatments and Management of Nasopharyngeal Carcinoma, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 45(3) (2025) e472460.","DOI":"10.1200\/EDBK-25-472460"},{"issue":"1","key":"661_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","volume":"37","author":"JE Brownell","year":"2010","unstructured":"Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 2010;37(1):102\u201311.","journal-title":"Mol Cell"},{"issue":"9","key":"661_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116(9):1515\u201323.","journal-title":"Blood"},{"issue":"5","key":"661_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.molcel.2006.08.010","volume":"23","author":"J Jin","year":"2006","unstructured":"Jin J, Arias EE, Chen J, Harper JW, Walter JC. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell. 2006;23(5):709\u201321.","journal-title":"Mol Cell"},{"issue":"10","key":"661_CR41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41419-024-07089-4","volume":"15","author":"ZX Chen","year":"2024","unstructured":"Chen ZX, Mu MY, Yang G, Qi H, Fu XB, Wang GS, Jiang WW, Huang BJ, Gao F. Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation. Cell Death Dis. 2024;15(10):734.","journal-title":"Cell Death Dis"},{"issue":"7","key":"661_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/dvdy.682","volume":"253","author":"Y Lin","year":"2024","unstructured":"Lin Y, Tang W, Huang P, Wang Z, Duan L, Jia C, Sun R, Liu L, Shen J. Denticleless E3 ubiquitin protein ligase (DTL) maintains the proliferation and differentiation of epidermis and hair follicles during skin development. Dev dynamics: official publication Am Association Anatomists. 2024;253(7):635\u201347.","journal-title":"Dev dynamics: official publication Am Association Anatomists"},{"issue":"1","key":"661_CR43","doi-asserted-by":"publisher","first-page":"28794","DOI":"10.1038\/s41598-024-80455-6","volume":"14","author":"B Khan","year":"2024","unstructured":"Khan B, Qahwaji R, Alfaifi MS, Athar T, Khan A, Mobashir M, Ashankyty I, Imtiyaz K, Alahmadi A, Rizvi MMA. Deciphering molecular landscape of breast cancer progression and insights from functional genomics and therapeutic explorations followed by in vitro validation. Sci Rep. 2024;14(1):28794.","journal-title":"Sci Rep"},{"issue":"1","key":"661_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-023-10755-z","volume":"23","author":"Y Tang","year":"2023","unstructured":"Tang Y, Lei Y, Gao P, Jia J, Du H, Wang Q, Yan Z, Zhang C, Liang G, Wang Y, Ma W, Xing N, Cheng L, Ren L. Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker. BMC Cancer. 2023;23(1):328.","journal-title":"BMC Cancer"},{"key":"661_CR45","doi-asserted-by":"crossref","unstructured":"Guo H, Tang Q, Zhao Y, Cheng J, Wang J, Liu D, Yan R, Lv D, Lu B, Wu M, Yu H, Leng H, Liu B, Liu M, Zhou K. MiR-3202-DTL signaling axis impedes NSCLC malignancy via regulating the ubiquitination-proteasome degradation of p21, Molecular and cellular biochemistry 480(7) (2025) 4183\u20134196.","DOI":"10.1007\/s11010-025-05239-6"},{"issue":"1","key":"661_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12885-022-09879-5","volume":"22","author":"G Singh","year":"2022","unstructured":"Singh G, Sharma SK, Singh SK. miR-34a negatively regulates cell cycle factor Cdt2\/DTL in HPV infected cervical cancer cells. BMC Cancer. 2022;22(1):777.","journal-title":"BMC Cancer"},{"issue":"1","key":"661_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41417-020-00292-3","volume":"29","author":"T Ma","year":"2022","unstructured":"Ma T, Hu Y, Guo Y, Zhang Q. Human umbilical vein endothelial cells-derived microRNA-203-containing extracellular vesicles alleviate non-small-cell lung cancer progression through modulating the DTL\/p21 axis. Cancer Gene Ther. 2022;29(1):87\u2013100.","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"661_CR48","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1101\/gad.2068611","volume":"25","author":"CG Havens","year":"2011","unstructured":"Havens CG, Walter JC. Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase. Genes Dev. 2011;25(15):1568\u201382.","journal-title":"Genes Dev"},{"issue":"18","key":"661_CR49","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1101\/gad.1676108","volume":"22","author":"T Abbas","year":"2008","unstructured":"Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev. 2008;22(18):2496\u2013506.","journal-title":"Genes Dev"},{"key":"661_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ebiom.2016.06.023","volume":"10","author":"M Benamar","year":"2016","unstructured":"Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Jr. Slingluff CL, Abbas T. Inactivation of the CRL4-CDT2-SET8\/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine. 2016;10:85\u2013100.","journal-title":"EBioMedicine"},{"issue":"1","key":"661_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12885-023-11768-4","volume":"24","author":"Q Liu","year":"2024","unstructured":"Liu Q, Yuan Y, Shang X, Xin L. Cyclin B2 impairs the p53 signaling in nasopharyngeal carcinoma. BMC Cancer. 2024;24(1):25.","journal-title":"BMC Cancer"},{"key":"661_CR52","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.omtn.2020.10.017","volume":"22","author":"L Zhou","year":"2020","unstructured":"Zhou L, Liu R, Liang X, Zhang S, Bi W, Yang M, He Y, Jin J, Li S, Yang X, Fu J, Zhang P. lncRNA RP11-624L4.1 Is Associated with Unfavorable Prognosis and Promotes Proliferation via the CDK4\/6-Cyclin D1-Rb-E2F1 Pathway in NPC, Molecular therapy. Nucleic acids. 2020;22:1025\u201339.","journal-title":"Nucleic acids"},{"issue":"9","key":"661_CR53","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41419-020-02925-9","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang B, Miao T, Shen X, Bao L, Zhang C, Yan C, Wei W, Chen J, Xiao L, Sun C, Du J, Li Y. EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization. Cell Death Dis. 2020;11(9):742.","journal-title":"Cell Death Dis"},{"issue":"25","key":"661_CR54","doi-asserted-by":"publisher","first-page":"21074","DOI":"10.18632\/oncotarget.4020","volume":"6","author":"JP Mak","year":"2015","unstructured":"Mak JP, Man WY, Chow JP, Ma HT, Poon RY. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Oncotarget. 2015;6(25):21074\u201384.","journal-title":"Oncotarget"},{"issue":"2","key":"661_CR55","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s10637-020-01017-x","volume":"39","author":"X Zhou","year":"2021","unstructured":"Zhou X, Sedarati F, Faller DV, Zhao D, Faessel HM, Chowdhury S, Bolleddula J, Li Y, Venkatakrishnan K, Papai Z. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investig New Drugs. 2021;39(2):488\u201398.","journal-title":"Investig New Drugs"},{"key":"661_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41420-020-00296-w","volume":"6","author":"J Ferris","year":"2020","unstructured":"Ferris J, Espona-Fiedler M, Hamilton C, Holohan C, Crawford N, McIntyre AJ, Roberts JZ, Wappett M, McDade SS, Longley DB, Coyle V. Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. Cell death discovery. 2020;6:61.","journal-title":"Cell death discovery"},{"issue":"1","key":"661_CR57","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13046-019-1358-x","volume":"38","author":"H Cui","year":"2019","unstructured":"Cui H, Wang Q, Lei Z, Feng M, Zhao Z, Wang Y, Wei G. DTL promotes cancer progression by PDCD4 ubiquitin-dependent degradation. J experimental Clin cancer research: CR. 2019;38(1):350.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"1","key":"661_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2010.09.014","volume":"40","author":"T Abbas","year":"2010","unstructured":"Abbas T, Shibata E, Park J, Jha S, Karnani N, Dutta A. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7\/Set8 for degradation. Mol Cell. 2010;40(1):9\u201321.","journal-title":"Mol Cell"},{"issue":"2","key":"661_CR59","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1535-7163.MCT-17-0083","volume":"17","author":"V Vanderdys","year":"2018","unstructured":"Vanderdys V, Allak A, Guessous F, Benamar M, Read PW, Jameson MJ, Abbas T. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors. Mol Cancer Ther. 2018;17(2):368\u201380.","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"661_CR60","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023;330(20):1961\u201370.","journal-title":"JAMA"},{"issue":"1","key":"661_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-024-00601-1","volume":"8","author":"X Liu","year":"2024","unstructured":"Liu X, Shen H, Zhang L, Huang W, Zhang S, Zhang B. Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma. NPJ precision Oncol. 2024;8(1):101.","journal-title":"NPJ precision Oncol"},{"issue":"8","key":"661_CR62","doi-asserted-by":"publisher","first-page":"e045417","DOI":"10.1136\/bmjopen-2020-045417","volume":"11","author":"M Xu","year":"2021","unstructured":"Xu M, Zang J, Luo S, Wang J, Li X. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study. BMJ open. 2021;11(8):e045417.","journal-title":"BMJ open"},{"issue":"6","key":"661_CR63","first-page":"463","volume":"47","author":"WR Luo","year":"2025","unstructured":"Luo WR. [Rethinking cancer], Zhonghua zhong liu za zhi. [Chinese J oncology]. 2025;47(6):463\u20137.","journal-title":"[Chinese J oncology]"},{"issue":"2","key":"661_CR64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cllc.2023.10.011","volume":"25","author":"A Qin","year":"2024","unstructured":"Qin A, Wells L, Malhotra B, Gadgeel S, Schneider BJ, Ramnath N, Rice JD, Kalemkerian GP. A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024;25(2):128\u201334.","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"661_CR65","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1111\/bcp.14078","volume":"85","author":"HM Faessel","year":"2019","unstructured":"Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019;85(11):2568\u201379.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"661_CR66","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","volume":"16","author":"NJ Short","year":"2023","unstructured":"Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023;16(1):73.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"661_CR67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-022-01264-w","volume":"15","author":"H Handa","year":"2022","unstructured":"Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1\/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J Hematol Oncol. 2022;15(1):56.","journal-title":"J Hematol Oncol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00661-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:32:13Z","timestamp":1781638333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00661-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00661-2","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest related to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}